Lexicon Pharmaceuticals (LXRX) Stock Forecast, Price Target & Predictions
LXRX Stock Forecast
Lexicon Pharmaceuticals stock forecast is as follows: an average price target of $6.00 (represents a 395.87% upside from LXRX’s last price of $1.21) and a rating consensus of 'Buy', based on 4 wall street analysts offering a 1-year stock forecast.
LXRX Price Target
The average price target for Lexicon Pharmaceuticals (LXRX) is $6.00 based on 1-year price targets from 4 Wall Street analysts in the past 3 months, with a price target range of $6.00 to $6.00. This represents a potential 395.87% upside from LXRX's last price of $1.21.
LXRX Analyst Ratings
According to 4 Wall Street analysts, Lexicon Pharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for LXRX stock is 0 'Strong Buy' (0.00%), 4 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Lexicon Pharmaceuticals Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Oct 18, 2024 | Roanna Ruiz | Leerink Partners | $6.00 | $2.01 | 198.51% | 395.87% |
The latest Lexicon Pharmaceuticals stock forecast, released on Oct 18, 2024 by Roanna Ruiz from Leerink Partners, set a price target of $6.00, which represents a 198.51% increase from the stock price at the time of the forecast ($2.01), and a 395.87% increase from LXRX last price ($1.21).
Lexicon Pharmaceuticals Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 1 | 1 | 1 |
| Avg Price Target | $6.00 | $6.00 | $6.00 |
| Last Closing Price | $1.21 | $1.21 | $1.21 |
| Upside/Downside | 395.87% | 395.87% | 395.87% |
In the current month, the average price target of Lexicon Pharmaceuticals stock is $6.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 395.87% increase as opposed to Lexicon Pharmaceuticals's last price of $1.21. This month's average price target is down 0.00% compared to last quarter, and down 0.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 23, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Oct 18, 2024 | Leerink Partners | Outperform | Outperform | Hold |
| Oct 17, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Sep 27, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Sep 03, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Aug 02, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Jun 17, 2024 | H.C. Wainwright | - | Buy | Initialise |
| May 31, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Jul 01, 2022 | Citigroup | Buy | Buy | Hold |
Lexicon Pharmaceuticals's last stock rating was published by H.C. Wainwright on Oct 23, 2024. The company gave LXRX a "Buy" rating, the same as its previous rate.
Lexicon Pharmaceuticals Financial Forecast
Lexicon Pharmaceuticals Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | Mar 16 | Mar 15 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | $702.00K | $162.00K | $317.00K | $24.00K | $28.00K | $39.00K | $35.00K | $37.00K | $234.00K | $27.00K | $199.00K | $6.63M | $9.16M | $8.00M | $8.73M | $294.45M | $9.68M | $9.22M | $25.21M | $18.29M | $12.49M | $1.79M |
| Avg Forecast | $14.10M | $10.80M | $7.90M | $6.25M | $9.79M | $2.93M | $3.44M | $1.40M | $1.25M | $2.06M | $66.67K | $33.33K | $50.00K | $50.00K | $100.00K | $50.00K | $13.50K | $2.23M | $66.67K | $91.34M | $8.84M | $7.78M | $10.26M | $12.00M | $28.52M | $13.29M | $28.57M | $23.29M | $11.03M | $1.86M |
| High Forecast | $14.10M | $10.80M | $7.90M | $6.25M | $9.79M | $3.29M | $3.44M | $1.40M | $1.40M | $2.06M | $66.67K | $33.33K | $50.00K | $50.00K | $100.00K | $50.00K | $13.50K | $2.23M | $66.67K | $91.34M | $8.84M | $7.78M | $10.26M | $12.00M | $28.52M | $13.29M | $34.29M | $27.95M | $13.24M | $2.24M |
| Low Forecast | $14.10M | $10.80M | $7.90M | $6.25M | $9.79M | $2.24M | $3.44M | $1.40M | $1.10M | $2.06M | $66.67K | $33.33K | $50.00K | $50.00K | $100.00K | $50.00K | $13.50K | $2.23M | $66.67K | $91.34M | $8.84M | $7.78M | $10.26M | $12.00M | $28.52M | $13.29M | $22.86M | $18.63M | $8.82M | $1.49M |
| # Analysts | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 9 | 8 | 7 | 6 | 5 | 5 | 5 | 5 | 13 | 13 | 16 | 10 |
| Surprise % | - | - | - | - | - | - | - | - | 0.56% | 0.08% | 4.75% | 0.72% | 0.56% | 0.78% | 0.35% | 0.74% | 17.33% | 0.01% | 2.98% | 0.07% | 1.04% | 1.03% | 0.85% | 24.55% | 0.34% | 0.69% | 0.88% | 0.79% | 1.13% | 0.96% |
Lexicon Pharmaceuticals's average Quarter revenue forecast for Mar 24 based on 1 analysts is $1.40M, with a low forecast of $1.40M, and a high forecast of $1.40M. LXRX's average Quarter revenue forecast represents a 99.43% increase compared to the company's last Quarter revenue of $702.00K (Dec 23).
Lexicon Pharmaceuticals EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | Mar 16 | Mar 15 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 9 | 8 | 7 | 6 | 5 | 5 | 5 | 5 | 13 | 13 | 16 | 10 |
| EBITDA | - | - | - | - | - | - | - | - | $-46.74M | $-49.63M | $-44.24M | $-30.11M | $-29.39M | $-22.41M | $-23.88M | $-23.26M | $-17.86M | $-20.75M | $-4.98M | $87.50M | $-63.05M | $-60.57M | $-45.01M | $226.18M | $-16.94M | $-15.78M | $-36.04M | $-41.32M | $-32.71M | $-26.02M |
| Avg Forecast | $-9.76M | $-7.48M | $-5.47M | $-4.33M | $-6.78M | $-2.03M | $-2.38M | $-20.33M | $-865.96K | $-1.43M | $-46.15K | $-21.75M | $-24.99M | $-34.62K | $-69.23K | $-23.26M | $-9.35K | $-22.05M | $-46.15K | $-63.23M | $-6.12M | $-65.84M | $-7.11M | $-8.30M | $-19.74M | $-16.50M | $-40.04M | $-50.18M | $-28.35M | $-26.92M |
| High Forecast | $-9.76M | $-7.48M | $-5.47M | $-4.33M | $-6.78M | $-1.55M | $-2.38M | $-16.27M | $-764.08K | $-1.43M | $-46.15K | $-17.40M | $-19.99M | $-34.62K | $-69.23K | $-18.61M | $-9.35K | $-17.64M | $-46.15K | $-63.23M | $-6.12M | $-52.67M | $-7.11M | $-8.30M | $-19.74M | $-13.20M | $-32.03M | $-40.14M | $-22.68M | $-21.53M |
| Low Forecast | $-9.76M | $-7.48M | $-5.47M | $-4.33M | $-6.78M | $-2.28M | $-2.38M | $-24.40M | $-967.84K | $-1.43M | $-46.15K | $-26.09M | $-29.98M | $-34.62K | $-69.23K | $-27.91M | $-9.35K | $-26.46M | $-46.15K | $-63.23M | $-6.12M | $-79.01M | $-7.11M | $-8.30M | $-19.74M | $-19.80M | $-48.05M | $-60.21M | $-34.02M | $-32.30M |
| Surprise % | - | - | - | - | - | - | - | - | 53.97% | 34.80% | 958.55% | 1.38% | 1.18% | 647.55% | 344.99% | 1.00% | 1910.55% | 0.94% | 107.92% | -1.38% | 10.31% | 0.92% | 6.33% | -27.24% | 0.86% | 0.96% | 0.90% | 0.82% | 1.15% | 0.97% |
9 analysts predict LXRX's average Quarter EBITDA for Dec 20 to be $-46.15K, with a high of $-46.15K and a low of $-46.15K. This is -100.05% lower than Lexicon Pharmaceuticals's previous annual EBITDA (Sep 20) of $87.50M.
Lexicon Pharmaceuticals Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | Mar 16 | Mar 15 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 9 | 8 | 7 | 6 | 5 | 5 | 5 | 5 | 13 | 13 | 16 | 10 |
| Net Income | - | - | - | - | - | - | - | - | $-48.24M | $-50.52M | $-44.90M | $-30.91M | $-30.71M | $-23.68M | $-25.17M | $-23.57M | $-18.07M | $-20.96M | $-5.50M | $82.60M | $-69.07M | $-66.61M | $-51.14M | $226.09M | $-23.02M | $-21.80M | $-42.08M | $-34.89M | $-34.88M | $-28.08M |
| Avg Forecast | $-55.95M | $-59.06M | $-59.06M | $-55.95M | $-47.95M | $-50.62M | $-55.01M | $-20.52M | $-67.50M | $-66.72M | $-54.29M | $-21.95M | $-25.28M | $-43.54M | $-50.08M | $-23.48M | $-49.63M | $-22.27M | $-85.98M | $114.10M | $-188.88M | $-72.40M | $-239.79M | $-69.94M | $-29.76M | $-22.79M | $-46.75M | $-42.37M | $-30.23M | $-29.04M |
| High Forecast | $-55.95M | $-59.06M | $-59.06M | $-55.95M | $-47.95M | $-47.64M | $-55.01M | $-16.42M | $-61.64M | $-66.72M | $-54.29M | $-17.56M | $-20.22M | $-43.54M | $-50.08M | $-18.78M | $-49.63M | $-17.81M | $-85.98M | $114.10M | $-188.88M | $-57.92M | $-239.79M | $-69.94M | $-29.76M | $-18.23M | $-37.40M | $-33.89M | $-24.19M | $-23.24M |
| Low Forecast | $-55.95M | $-59.06M | $-59.06M | $-55.95M | $-47.95M | $-53.59M | $-55.01M | $-24.63M | $-70.44M | $-66.72M | $-54.29M | $-26.34M | $-30.33M | $-43.54M | $-50.08M | $-28.17M | $-49.63M | $-26.72M | $-85.98M | $114.10M | $-188.88M | $-86.88M | $-239.79M | $-69.94M | $-29.76M | $-27.35M | $-56.10M | $-50.84M | $-36.28M | $-34.85M |
| Surprise % | - | - | - | - | - | - | - | - | 0.71% | 0.76% | 0.83% | 1.41% | 1.21% | 0.54% | 0.50% | 1.00% | 0.36% | 0.94% | 0.06% | 0.72% | 0.37% | 0.92% | 0.21% | -3.23% | 0.77% | 0.96% | 0.90% | 0.82% | 1.15% | 0.97% |
Lexicon Pharmaceuticals's average Quarter net income forecast for Dec 20 is $-85.98M, with a range of $-85.98M to $-85.98M. LXRX's average Quarter net income forecast represents a -204.08% decrease compared to the company's last Quarter net income of $82.60M (Sep 20).
Lexicon Pharmaceuticals SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | Mar 16 | Mar 15 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 9 | 8 | 7 | 6 | 5 | 5 | 5 | 5 | 13 | 13 | 16 | 10 |
| SG&A | - | - | - | - | - | - | - | - | $32.61M | $32.23M | $30.01M | $19.14M | $16.33M | $12.58M | $10.69M | $8.49M | $7.94M | $8.26M | $6.43M | $12.00M | $14.11M | $14.69M | $14.56M | $13.90M | $14.26M | $14.11M | $14.86M | $14.87M | $8.40M | $5.70M |
| Avg Forecast | $1.55B | $1.19B | $871.00M | $689.08M | $1.08B | $322.80M | $378.78M | $154.35M | $137.91M | $227.14M | $7.35M | $3.68M | $5.51M | $5.51M | $11.03M | $5.51M | $1.49M | $246.42M | $7.35M | $10.07B | $974.09M | $858.04M | $1.13B | $1.32B | $3.14B | $1.47B | $16.51M | $18.06M | $7.28M | $205.54M |
| High Forecast | $1.55B | $1.19B | $871.00M | $689.08M | $1.08B | $362.89M | $378.81M | $154.35M | $154.13M | $227.15M | $7.35M | $3.68M | $5.51M | $5.51M | $11.03M | $5.51M | $1.49M | $246.42M | $7.35M | $10.07B | $974.09M | $858.04M | $1.13B | $1.32B | $3.14B | $1.47B | $19.81M | $21.67M | $8.73M | $246.65M |
| Low Forecast | $1.55B | $1.19B | $871.00M | $689.08M | $1.08B | $246.72M | $378.76M | $154.35M | $121.68M | $227.13M | $7.35M | $3.68M | $5.51M | $5.51M | $11.03M | $5.51M | $1.49M | $246.42M | $7.35M | $10.07B | $974.09M | $858.04M | $1.13B | $1.32B | $3.14B | $1.47B | $13.21M | $14.45M | $5.82M | $164.43M |
| Surprise % | - | - | - | - | - | - | - | - | 0.24% | 0.14% | 4.08% | 5.21% | 2.96% | 2.28% | 0.97% | 1.54% | 5.33% | 0.03% | 0.88% | 0.00% | 0.01% | 0.02% | 0.01% | 0.01% | 0.00% | 0.01% | 0.90% | 0.82% | 1.15% | 0.03% |
Lexicon Pharmaceuticals's average Quarter SG&A projection for Mar 24 is $154.35M, based on 1 Wall Street analysts, with a range of $154.35M to $154.35M. The forecast indicates a 373.38% rise compared to LXRX last annual SG&A of $32.61M (Dec 23).
Lexicon Pharmaceuticals EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | Mar 16 | Mar 15 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 9 | 8 | 7 | 6 | 5 | 5 | 5 | 5 | 13 | 13 | 16 | 10 |
| EPS | - | - | - | - | - | - | - | - | $-0.20 | $-0.21 | $-0.22 | $-0.16 | $-0.16 | $-0.14 | $-0.17 | $-0.16 | $-0.13 | $-0.15 | $-0.04 | $0.77 | $-0.65 | $-0.63 | $-0.48 | $2.13 | $-0.22 | $-0.21 | $-0.40 | $-0.33 | $-0.34 | $-0.28 |
| Avg Forecast | $-0.18 | $-0.19 | $-0.19 | $-0.18 | $-0.15 | $-0.16 | $-0.18 | $-0.18 | $-0.22 | $-0.21 | $-0.17 | $-0.18 | $-0.13 | $-0.14 | $-0.16 | $-0.17 | $-0.16 | $-0.16 | $-0.28 | $0.37 | $-0.61 | $-0.69 | $-0.77 | $-0.23 | $-0.10 | $-0.22 | $-0.50 | $-0.51 | $-0.26 | $-0.30 |
| High Forecast | $-0.18 | $-0.19 | $-0.19 | $-0.18 | $-0.15 | $-0.15 | $-0.18 | $-0.18 | $-0.20 | $-0.21 | $-0.17 | $-0.18 | $-0.13 | $-0.14 | $-0.16 | $-0.17 | $-0.16 | $-0.16 | $-0.28 | $0.37 | $-0.61 | $-0.69 | $-0.77 | $-0.23 | $-0.10 | $-0.22 | $-0.40 | $-0.41 | $-0.21 | $-0.24 |
| Low Forecast | $-0.18 | $-0.19 | $-0.19 | $-0.18 | $-0.15 | $-0.17 | $-0.18 | $-0.18 | $-0.23 | $-0.21 | $-0.17 | $-0.18 | $-0.13 | $-0.14 | $-0.16 | $-0.17 | $-0.16 | $-0.16 | $-0.28 | $0.37 | $-0.61 | $-0.69 | $-0.77 | $-0.23 | $-0.10 | $-0.22 | $-0.60 | $-0.61 | $-0.31 | $-0.36 |
| Surprise % | - | - | - | - | - | - | - | - | 0.92% | 0.98% | 1.26% | 0.89% | 1.20% | 1.00% | 1.06% | 0.97% | 0.81% | 0.95% | 0.14% | 2.10% | 1.07% | 0.91% | 0.62% | -9.47% | 2.30% | 0.94% | 0.80% | 0.65% | 1.31% | 0.93% |
According to 9 Wall Street analysts, Lexicon Pharmaceuticals's projected average Quarter EPS for Dec 20 is $-0.28, with a low estimate of $-0.28 and a high estimate of $-0.28. This represents a -135.92% decrease compared to LXRX previous annual EPS of $0.77 (Sep 20).
Lexicon Pharmaceuticals Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| HEPA | Hepion Pharmaceuticals | $0.63 | $70.00 | 11011.11% | Buy |
| ELEV | Elevation Oncology | $0.52 | $9.00 | 1630.77% | Buy |
| XFOR | X4 Pharmaceuticals | $0.53 | $3.67 | 592.45% | Buy |
| LXRX | Lexicon Pharmaceuticals | $1.21 | $6.00 | 395.87% | Buy |
| DAWN | Day One Biopharmaceuticals | $14.81 | $38.80 | 161.99% | Buy |
| TERN | Terns Pharmaceuticals | $7.10 | $14.25 | 100.70% | Buy |
| MREO | Mereo BioPharma Group | $4.01 | $6.75 | 68.33% | Buy |
| MCRB | Seres Therapeutics | $0.81 | $1.25 | 54.32% | Buy |
| IBRX | ImmunityBio | $5.20 | $8.00 | 53.85% | Buy |
| ARDX | Ardelyx | $5.89 | $8.75 | 48.56% | Buy |
| EFTR | eFFECTOR Therapeutics | - | $5.50 | - | Buy |
| HOOK | HOOKIPA Pharma | $3.76 | $3.00 | -20.21% | Buy |
LXRX Forecast FAQ
Is Lexicon Pharmaceuticals a good buy?
Yes, according to 4 Wall Street analysts, Lexicon Pharmaceuticals (LXRX) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 4 'Buy' recommendations, accounting for 100.00% of LXRX's total ratings.
What is LXRX's price target?
Lexicon Pharmaceuticals (LXRX) average price target is $6 with a range of $6 to $6, implying a 395.87% from its last price of $1.21. The data is based on 4 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Lexicon Pharmaceuticals stock go up soon?
According to Wall Street analysts' prediction for LXRX stock, the company can go up by 395.87% (from the last price of $1.21 to the average price target of $6), up by 395.87% based on the highest stock price target, and up by 395.87% based on the lowest stock price target.
Can Lexicon Pharmaceuticals stock reach $2?
LXRX's average twelve months analyst stock price target of $6 supports the claim that Lexicon Pharmaceuticals can reach $2 in the near future.
What is Lexicon Pharmaceuticals's current price target trend?
1 Wall Street analyst forecast a $6 price target for Lexicon Pharmaceuticals (LXRX) this month, up 395.87% from its last price of $1.21. Compared to the last 3 and 12 months, the average price target increased by 395.87% and increased by 395.87%, respectively.
What are Lexicon Pharmaceuticals's analysts' financial forecasts?
Lexicon Pharmaceuticals's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $17.56M (high $17.92M, low $16.87M), average EBITDA is $-31.518M (high $-26.974M, low $-35.836M), average net income is $-174M (high $-167M, low $-181M), average SG&A $1.94B (high $1.98B, low $1.86B), and average EPS is $-0.674 (high $-0.664, low $-0.684). LXRX's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $39.05M (high $39.05M, low $39.05M), average EBITDA is $-27.034M (high $-27.034M, low $-27.034M), average net income is $-230M (high $-230M, low $-230M), average SG&A $4.31B (high $4.31B, low $4.31B), and average EPS is $-0.74 (high $-0.74, low $-0.74).
Did the LXRX's actual financial results beat the analysts' financial forecasts?
Based on Lexicon Pharmaceuticals's last annual report (Dec 2023), the company's revenue was $1.2M, which missed the average analysts forecast of $3.41M by -64.70%. Apple's EBITDA was $-172M, beating the average prediction of $-24.084M by 613.14%. The company's net income was $-176M, missing the average estimation of $-210M by -16.56%. Apple's SG&A was $113.98M, missing the average forecast of $376.08M by -69.69%. Lastly, the company's EPS was $-0.79, beating the average prediction of $-0.786 by 0.53%. In terms of the last quarterly report (Dec 2023), Lexicon Pharmaceuticals's revenue was $702K, missing the average analysts' forecast of $1.25M by -43.88%. The company's EBITDA was $-46.737M, beating the average prediction of $-866K by 5297.14%. Lexicon Pharmaceuticals's net income was $-48.244M, missing the average estimation of $-67.504M by -28.53%. The company's SG&A was $32.61M, missing the average forecast of $137.91M by -76.36%. Lastly, the company's EPS was $-0.2, missing the average prediction of $-0.217 by -7.91%